Published in Endocrinology on February 01, 2002
Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell (2007) 1.19
Ghrelin: integrative neuroendocrine peptide in health and disease. Ann Surg (2004) 1.06
Ghrelin treatment of cachectic patients with chronic obstructive pulmonary disease: a multicenter, randomized, double-blind, placebo-controlled trial. PLoS One (2012) 0.96
Regulation of ERK1/2 activity by ghrelin-activated growth hormone secretagogue receptor 1A involves a PLC/PKCvarepsilon pathway. Br J Pharmacol (2006) 0.92
Ghrelin and the growth hormone secretagogue receptor constitute a novel autocrine pathway in astrocytoma motility. J Biol Chem (2006) 0.91
Ghrelin in fetal thyroid and follicular tumors and cell lines: expression and effects on tumor growth. Am J Pathol (2003) 0.87
Ghrelin localization in rat and human thyroid and parathyroid glands and tumours. Histochem Cell Biol (2005) 0.82
A role of ghrelin in canine mammary carcinoma cells proliferation, apoptosis and migration. BMC Vet Res (2012) 0.81
An immunohistochemical study of the localization and developmental expression of ghrelin and its functional receptor in the ovine placenta. Reprod Biol Endocrinol (2007) 0.78
Lentivirus-mediated shRNA interference of ghrelin receptor blocks proliferation in the colorectal cancer cells. Cancer Med (2016) 0.75
Prognostic Significance of Preoperative and Postoperative Plasma Levels of Ghrelin in Gastric Cancer: 3-Year Survival Study. Clin Transl Gastroenterol (2017) 0.75
Effects of ghrelin on the apoptosis of human neutrophils in vitro. Int J Mol Med (2016) 0.75
Adjuvant mitotane treatment for adrenocortical carcinoma. N Engl J Med (2007) 6.58
Biological, physiological, pathophysiological, and pharmacological aspects of ghrelin. Endocr Rev (2004) 3.79
Poorly differentiated thyroid carcinoma: the Turin proposal for the use of uniform diagnostic criteria and an algorithmic diagnostic approach. Am J Surg Pathol (2007) 2.75
Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. Lancet Oncol (2008) 2.32
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer (2006) 2.27
Hypopituitarism. Lancet (2007) 2.27
Cell membrane reactivity of MIB-1 antibody to Ki67 in human tumors: fact or artifact? Appl Immunohistochem Mol Morphol (2007) 2.21
Loss of miR-200c expression induces an aggressive, invasive, and chemoresistant phenotype in non-small cell lung cancer. Mol Cancer Res (2010) 2.04
Ghrelin and des-acyl ghrelin inhibit cell death in cardiomyocytes and endothelial cells through ERK1/2 and PI 3-kinase/AKT. J Cell Biol (2002) 1.97
The prognostic and predictive role of histology in advanced non-small cell lung cancer: a literature review. J Thorac Oncol (2008) 1.94
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: towards a standardized approach to the diagnosis of gastroenteropancreatic neuroendocrine tumors and their prognostic stratification. Neuroendocrinology (2009) 1.92
The grey zone between pure (neuro)endocrine and non-(neuro)endocrine tumours: a comment on concepts and classification of mixed exocrine-endocrine neoplasms. Virchows Arch (2006) 1.82
The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group. Lung Cancer (2011) 1.62
Hypothalamopituitary dysfunction following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a systematic review. JAMA (2007) 1.59
The cut-off limits of the GH response to GH-releasing hormone-arginine test related to body mass index. Eur J Endocrinol (2005) 1.59
MicroRNA-30a inhibits epithelial-to-mesenchymal transition by targeting Snai1 and is downregulated in non-small cell lung cancer. Int J Cancer (2011) 1.58
Gemcitabine plus metronomic 5-fluorouracil or capecitabine as a second-/third-line chemotherapy in advanced adrenocortical carcinoma: a multicenter phase II study. Endocr Relat Cancer (2010) 1.56
Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology. Clin Chem Lab Med (2014) 1.49
Ghrelin: a metabolic signal affecting the reproductive system. Cytokine Growth Factor Rev (2009) 1.48
Endocrine function is altered in chronic migraine patients with medication-overuse. Headache (2006) 1.47
Expression of ghrelin and of the GH secretagogue receptor by pancreatic islet cells and related endocrine tumors. J Clin Endocrinol Metab (2002) 1.45
A DNA vaccine against ERBB2 impairs chemical carcinogenesis in random-bred hamsters. Cancer Prev Res (Phila) (2011) 1.43
Ghrelin stimulates, whereas des-octanoyl ghrelin inhibits, glucose output by primary hepatocytes. J Clin Endocrinol Metab (2004) 1.39
ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology (2012) 1.38
RAS mutations are the predominant molecular alteration in poorly differentiated thyroid carcinomas and bear prognostic impact. J Clin Endocrinol Metab (2009) 1.32
Dual effects of IGFBP-3 on endothelial cell apoptosis and survival: involvement of the sphingolipid signaling pathways. FASEB J (2004) 1.32
Residual pituitary function after brain injury-induced hypopituitarism: a prospective 12-month study. J Clin Endocrinol Metab (2005) 1.32
Extracellular vesicles as an emerging mechanism of cell-to-cell communication. Endocrine (2012) 1.32
IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. J Neurooncol (2011) 1.31
Poorly differentiated carcinoma of the thyroid: validation of the Turin proposal and analysis of IMP3 expression. Mod Pathol (2010) 1.29
Neuroendocrine differentiation in breast cancer: established facts and unresolved problems. Semin Diagn Pathol (2010) 1.29
Traumatic brain injury and subarachnoid haemorrhage are conditions at high risk for hypopituitarism: screening study at 3 months after the brain injury. Clin Endocrinol (Oxf) (2004) 1.29
Expression pattern of receptor activator of NFκB (RANK) in a series of primary solid tumors and related bone metastases. J Cell Physiol (2011) 1.27
Growth hormone-releasing hormone promotes survival of cardiac myocytes in vitro and protects against ischaemia-reperfusion injury in rat heart. Cardiovasc Res (2009) 1.26
Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol (2007) 1.25
Phosphorylated ERalpha, HIF-1alpha, and MAPK signaling as predictors of primary endocrine treatment response and resistance in patients with breast cancer. J Clin Oncol (2008) 1.25
Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab (2012) 1.24
Neuroendocrine and peripheral activities of ghrelin: implications in metabolism and obesity. Eur J Pharmacol (2002) 1.24
Obestatin promotes survival of pancreatic beta-cells and human islets and induces expression of genes involved in the regulation of beta-cell mass and function. Diabetes (2007) 1.22
Ghrelin and des-acyl ghrelin promote differentiation and fusion of C2C12 skeletal muscle cells. Mol Biol Cell (2007) 1.19
Role of Pax2 in apoptosis resistance and proinvasive phenotype of Kaposi's sarcoma cells. J Biol Chem (2003) 1.15
Inhibition of erythropoiesis in malaria anemia: role of hemozoin and hemozoin-generated 4-hydroxynonenal. Blood (2010) 1.15
MET mutations in cancers of unknown primary origin (CUPs). Hum Mutat (2010) 1.13
The endocrine response to ghrelin as a function of gender in humans in young and elderly subjects. J Clin Endocrinol Metab (2003) 1.12
Non-small cell lung cancer exhibits transcript overexpression of genes associated with homologous recombination and DNA replication pathways. Cancer Res (2009) 1.12
The oxytocin receptor antagonist atosiban inhibits cell growth via a "biased agonist" mechanism. J Biol Chem (2005) 1.11
Effects of Src kinase inhibition induced by dasatinib in non-small cell lung cancer cell lines treated with cisplatin. Mol Cancer Ther (2009) 1.11
Epidermal growth factor receptor gene in primary tumor and metastatic sites from non-small cell lung cancer. J Thorac Oncol (2009) 1.10
Ki-67 antigen in lung neuroendocrine tumors: unraveling a role in clinical practice. J Thorac Oncol (2014) 1.09
Unraveling the role of the ghrelin gene peptides in the endocrine pancreas. J Mol Endocrinol (2010) 1.09
Chromogranin A expression in patients with hormone naïve prostate cancer predicts the development of hormone refractory disease. J Urol (2007) 1.08
Cancers of unknown primary origin: current perspectives and future therapeutic strategies. J Transl Med (2012) 1.08
Systemic cancer metastasis in a meningioma: report of two cases and review of the literature. Clin Neurol Neurosurg (2008) 1.08
Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection. J Clin Endocrinol Metab (2015) 1.07
Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol (2013) 1.07
Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure. Virchows Arch (2006) 1.07
Characterization of a novel peripheral pro-lipolytic mechanism in mice: role of VGF-derived peptide TLQP-21. Biochem J (2012) 1.06
Unacylated ghrelin acts as a potent insulin secretagogue in glucose-stimulated conditions. Am J Physiol Endocrinol Metab (2007) 1.06
Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology (2009) 1.06
Polymerase eta mRNA expression predicts survival of non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res (2009) 1.05
Expression of ghrelin and biological activity of specific receptors for ghrelin and des-acyl ghrelin in human prostate neoplasms and related cell lines. Eur J Endocrinol (2004) 1.05
ΔNp63 (p40) and thyroid transcription factor-1 immunoreactivity on small biopsies or cellblocks for typing non-small cell lung cancer: a novel two-hit, sparing-material approach. J Thorac Oncol (2012) 1.04
Effect of food restriction on ghrelin in normal-cycling female rats and in pregnancy. Obes Res (2002) 1.04
Differential Thymidylate Synthase Expression in Different Variants of Large-Cell Carcinoma of the Lung. Clin Cancer Res (2009) 1.03
Metabolic and endocrine effects of physiological increments in plasma ghrelin concentrations. Nutr Metab Cardiovasc Dis (2005) 1.03
Second Italian consensus conference on malignant pleural mesothelioma: state of the art and recommendations. Cancer Treat Rev (2012) 1.03
Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol (2002) 1.03
A reevaluation of the clinical significance of histological subtyping of non--small-cell lung carcinoma: diagnostic algorithms in the era of personalized treatments. Int J Surg Pathol (2009) 1.02
Targeted next-generation sequencing of cancer genes in advanced stage malignant pleural mesothelioma: a retrospective study. J Thorac Oncol (2015) 1.02
Diagnostic accuracy and clinical impact of imaging-guided needle biopsy of renal masses. Retrospective analysis on 150 cases. Eur Radiol (2010) 1.02
Cardiovascular actions of the ghrelin gene-derived peptides and growth hormone-releasing hormone. Exp Biol Med (Maywood) (2011) 1.02
Multiparametric molecular characterization of pulmonary sarcomatoid carcinoma reveals a nonrandom amplification of anaplastic lymphoma kinase (ALK) gene. Lung Cancer (2012) 1.02